It was all going so well. Less than two months ago positive phase I data with Oxurion's THR-149, a novel plasma kallikrein inhibitor, spurred hopes that the Belgian biotech's transformation could be under way. Those expectations were comprehensively dashed today with the failure of the group's lead pipeline project, THR-317, in diabetic macular oedema.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,